Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St set to open lower after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| Actinium Pharmaceuticals, Inc. (NYSE: ATNM) | Delayed: 1.52 -0.08 (5%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.60 | 52 Week High | $3.50 | |||
| Open | $1.60 | 52 Week Low | $0.86 | |||
| Day High | $1.63 | P/E | N/A | |||
| Day Low | $1.50 | EPS | $-7.61 | |||
| Volume | 65,904 | |||||
